Thyroid dysfunction in Chinese hepatitis C patients: Prevalence and correlation with TPOAb and CXCL10

World Journal of Gastroenterology

Volumn 21, Issue 33, 2015, Pages 9765-9773

  Zhang, Ren Wen ^a   Shao, Cui Ping ^a   Huo, Na ^a   Li, Min Ran ^a   Xi, Hong Li ^a   Yu, Min ^a   Xu, Xiao Yuan ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

China; CXC chemokine ligand 10; Peginterferon alfa 2a ribavirin; Thyroid dysfunction; Thyroid peroxidase antibody

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; LIOTHYRONINE; PEGINTERFERON ALPHA2A; RIBAVIRIN; THYROGLOBULIN ANTIBODY; THYROID HORMONE; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; ALPHA INTERFERON; ANTIVIRUS AGENT; AUTOANTIBODY; AUTOANTIGEN; BIOLOGICAL MARKER; CXCL10 PROTEIN, HUMAN; IODIDE PEROXIDASE; IRON BINDING PROTEIN; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN; THYROID MICROSOMAL ANTIBODIES; TPO PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CHEMOLUMINESCENCE; CHINESE; CHRONIC HEPATITIS C; CORRELATIONAL STUDY; FEMALE; FOLLOW UP; FREE THYROXINE INDEX; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; INVESTIGATIVE PROCEDURES; LIOTHYRONINE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; PREVALENCE; REAL TIME POLYMERASE CHAIN REACTION; THYROID DISEASE; THYROID FUNCTION; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; YOUNG ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CHINA; COMBINATION DRUG THERAPY; HEPATITIS C, CHRONIC; IMMUNOLOGY; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; THYROID DISEASES; THYROID GLAND; TIME FACTOR; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; AUTOANTIBODIES; AUTOANTIGENS; BIOMARKERS; CHEMOKINE CXCL10; CHINA; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; IODIDE PEROXIDASE; IRON-BINDING PROTEINS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREVALENCE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK FACTORS; SEX FACTORS; THYROID DISEASES; THYROID GLAND; TIME FACTORS; TREATMENT OUTCOME;

EID: 84941729584     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i33.9765     Document Type: Article

References (34)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of agespecific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-1342 [PMID: 23172780 DOI: 10.1002/hep.26141]
2. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29 Suppl 1: 74-81 [PMID: 19207969 DOI: 10.1111/j.1478-3231.2008.01934.x]
3. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492 [PMID: 9819446]
4. Yu ML, Dai CY, Huang JF, Hou NJ, Lee LP, Hsieh MY, Chiu CF, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56: 553-559 [PMID: 16956917 DOI: 10.1136/gut.2006.102558]
5. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003; 124: 1711-1719 [PMID: 12761728 DOI: 10.1016/S0016-5085(03)00394-9]
6. Hsieh MY, Dai CY, Lee LP, Huang JF, Tsai WC, Hou NJ, Lin ZY, Chen SC, Wang LY, Chang WY, Chuang WL, Yu ML. Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C. J Clin Pathol 2008; 61: 333-337 [PMID: 17545561 DOI: 10.1136/jcp.2006.046276]
7. Huang JF, Chuang WL, Yu ML, Yu SH, Huang CF, Huang CI, Yeh ML, Hsieh MH, Yang JF, Lin ZY, Chen SC, Dai CY, Chang WY. Hepatitis C virus infection and metabolic syndrome-a community-based study in an endemic area of Taiwan. Kaohsiung J Med Sci 2009; 25: 299-305 [PMID: 19560994 DOI: 10.1016/S1607-551X(09)70520-0]
8. Tomer Y, Blackard JT, Akeno N. Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North Am 2007; 36: 1051-1066; x-xi [PMID: 17983936 DOI: 10.1016/j.ecl.2007.07.001]
9. Carella C, Mazziotti G, Amato G, Braverman LE, Roti E. Clinical review 169: Interferon-alpha-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab 2004; 89: 3656-3661 [PMID: 15292282 DOI: 10.1210/jc.2004-0627]
10. Abe T, Fukuhara T, Wen X, Ninomiya A, Moriishi K, Maehara Y, Takeuchi O, Kawai T, Akira S, Matsuura Y. CD44 participates in IP-10 induction in cells in which hepatitis C virus RNA is replicating, through an interaction with Toll-like receptor 2 and hyaluronan. J Virol 2012; 86: 6159-6170 [PMID: 22491449 DOI: 10.1128/JVI.06872-11]
11. Antonelli A, Fallahi P, Ferrari SM, Sebastiani M, Manfredi A, Mazzi V, Fabiani S, Centanni M, Marchi S, Ferri C. Circulating CXCL11 and CXCL10 are increased in hepatitis C-associated cryoglobulinemia in the presence of autoimmune thyroiditis. Mod Rheumatol 2012; 22: 659-667 [PMID: 22160826 DOI: 10.1007/s10165-011-0565-x]
12. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Romagnani P, Grosso M, Ferrannini E, Serio M. Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper-or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur J Endocrinol 2006; 154: 651-658 [PMID: 16645011 DOI: 10.1530/eje.1.02137]
13. Antonelli A, Ferri C, Ferrari SM, Colaci M, Sansonno D, Fallahi P. Endocrine manifestations of hepatitis C virus infection. Nat Clin Pract Endocrinol Metab 2009; 5: 26-34 [PMID: 19079271 DOI: 10.1038/ncpendmet1027]
14. Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology 2006; 43: 661-672 [PMID: 16557537 DOI: 10.1002/hep.21146]
15. Shao C, Huo N, Zhao L, Gao Y, Fan X, Zheng Y, Wang L, Lu H, Xu X, Guo X. The presence of thyroid peroxidase antibody of IgG2 subclass is a risk factor for thyroid dysfunction in chronic hepatitis C patients. Eur J Endocrinol 2013; 168: 717-722 [PMID: 23419250 DOI: 10.1530/EJE-12-0775]
16. Carella C, Mazziotti G, Morisco F, Rotondi M, Cioffi M, Tuccillo C, Sorvillo F, Caporaso N, Amato G. The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virusrelated chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism. Eur J Endocrinol 2002; 146: 743-749 [PMID: 12039693 DOI: 10.1530/eje.0.1460743]
17. Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party; McCaughan GW, Omata M, Amarapurkar D, Bowden S, Chow WC, Chutaputti A, Dore G, Gane E, Guan R, Hamid SS, Hardikar W, Hui CK, Jafri W, Jia JD, Lai MY, Wei L, Leung N, Piratvisuth T, Sarin S, Sollano J, Tateishi R. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007; 22: 615-633 [PMID: 17444847 DOI: 10.1111/j.1440-1746.2007.04883.x]
18. Wang LF, Wu CH, Shan Y, Fan XH, Huo N, Lu HY, Xu XY. Prevalence of abnormal glycometabolism in patients with chronic hepatitis C and related risk factors in China. Chin Med J (Engl) 2011; 124: 183-188 [PMID: 21362362 DOI: 10.3760/cma.j.issn.03 66-6999.2011.02.005]
19. Bai L, Feng ZR, Lu HY, Li WG, Yu M, Xu XY. Prevalence of antinuclear and anti-liver-kidney-microsome type-1 antibodies in patients with chronic hepatitis C in China. Chin Med J (Engl) 2009; 122: 5-9 [PMID: 19187609 DOI: 10.3760/cma.j.issn.0366-6 999.2009.01.002]
20. Schultz M, Müller R, von zur Mühlen A, Brabant G. Induction of hyperthyroidism by interferon-alpha-2b. Lancet 1989; 1: 1452 [PMID: 2567459 DOI: 10.1016/S0140-6736(89)90157-8]
21. Gisslinger H, Gilly B, Woloszczuk W, Mayr WR, Havelec L, Linkesch W, Weissel M. Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha. Clin Exp Immunol 1992; 90: 363-367 [PMID: 1458673 DOI: 10.1111/j.1365-2249.1992.tb05852.x]
22. Fentiman IS, Thomas BS, Balkwill FR, Rubens RD, Hayward JL. Primary hypothyroidism associated with interferon therapy of breast cancer. Lancet 1985; 1: 1166 [PMID: 2860373 DOI: 10.1016/S0140-6736(85)92475-4]
23. Costelloe SJ, Wassef N, Schulz J, Vaghijiani T, Morris C, Whiting S, Thomas M, Dusheiko G, Jacobs M, Vanderpump MP. Thyroid dysfunction in a UK hepatitis C population treated with interferonalpha and ribavirin combination therapy. Clin Endocrinol (Oxf) 2010; 73: 249-256 [PMID: 20148905 DOI: 10.1111/j.1365-2265.2010.03785.x]
24. Jamil KM, Leedman PJ, Kontorinis N, Tarquinio L, Nazareth S, McInerney M, Connelly C, Flexman J, Burke V, Metcalf C, Cheng W. Interferon-induced thyroid dysfunction in chronic hepatitis C. J Gastroenterol Hepatol 2009; 24: 1017-1023 [PMID: 19054259 DOI: 10.1111/j.1440-1746.2008.05690.x]
25. Tran HA, Attia JR, Jones TL, Batey RG. Pegylated interferonalpha2beta in combination with ribavirin does not aggravate thyroid dysfunction in comparison to regular interferon-alpha2beta in a hepatitis C population: meta-analysis. J Gastroenterol Hepatol 2007; 22: 472-476 [PMID: 17376035 DOI: 10.1111/j.1440-1746.2006.04771.x]
26. Tam RC, Pai B, Bard J, Lim C, Averett DR, Phan UT, Milovanovic T. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J Hepatol 1999; 30: 376-382 [PMID: 10190717 DOI: 10.1016/S0168-8278(99)80093-2]
27. Hsieh MC, Yu ML, Chuang WL, Shin SJ, Dai CY, Chen SC, Lin ZY, Hsieh MY, Liu JF, Wang LY, Chang WY. Virologic factors related to interferon-alpha-induced thyroid dysfunction in patients with chronic hepatitis C. Eur J Endocrinol 2000; 142: 431-437 [PMID: 10802518 DOI: 10.1530/eje.0.1420431]
28. Huang JF, Chuang WL, Dai CY, Chen SC, Lin ZY, Lee LP, Lee PL, Wang LY, Hsieh MY, Chang WY, Yu ML. The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferon-alpha and ribavirin combination therapy. J Viral Hepat 2006; 13: 396-401 [PMID: 16842442 DOI: 10.1111/j.1365-2893.2005.00705.x]
29. Baudin E, Marcellin P, Pouteau M, Colas-Linhart N, Le Floch JP, Lemmonier C, Benhamou JP, Bok B. Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C. Clin Endocrinol (Oxf) 1993; 39: 657-661 [PMID: 8287583 DOI: 10.1111/j.1365-2265.1993.tb02423.x]
30. Gelu-Simeon M, Burlaud A, Young J, Pelletier G, Buffet C. Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C. World J Gastroenterol 2009; 15: 328-333 [PMID: 19140232 DOI: 10.3748/wjg.15.328]
31. Bini EJ, Mehandru S. Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study. Arch Intern Med 2004; 164: 2371-2376 [PMID: 15557418 DOI: 10.1001/archinte.164.21.2371]
32. Mazziotti G, Sorvillo F, Piscopo M, Morisco F, Cioffi M, Stornaiuolo G, Gaeta GB, Molinari AM, Lazarus JH, Amato G, Carella C. Innate and acquired immune system in patients developing interferon-alpha-related autoimmune thyroiditis: a prospective study. J Clin Endocrinol Metab 2005; 90: 4138-4144 [PMID: 15855253 DOI: 10.1210/jc.2005-0093]
33. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Buonamano A, Ferrannini E, Serio M. High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab 2004; 89: 5496-5499 [PMID: 15531503 DOI: 10.1210/jc.2004-0977]
34. Rotondi M, Minelli R, Magri F, Leporati P, Romagnani P, Baroni MC, Delsignore R, Serio M, Chiovato L. Serum CXCL10 levels and occurrence of thyroid dysfunction in patients treated with interferon-alpha therapy for hepatitis C virus-related hepatitis. Eur J Endocrinol 2007; 156: 409-414 [PMID: 17389454 DOI: 10.1530/EJE-06-0735]